Pharmacoeconomics of thrombosis management

Pharmacotherapy

Volumn 24, Issue 7 II, 2004, Pages

  Hawkins, David ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Fondaparinux; Orthopedic surgery; Pharmacoeconomics; Thrombosis management; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEALTH ECONOMICS; HUMAN; LUNG EMBOLISM; MORBIDITY; MORTALITY; PHARMACOECONOMICS; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM;

COST-BENEFIT ANALYSIS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 3042846896     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.10.95S.36123     Document Type: Review

References (31)

1. American College of Chest Physicians. Sixth ACCP consensus conference on antithrombotic therapy. Chest 2001;119(suppl 1):S1-370.
2. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl 1):S132-75.
3. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996;93:2212-45.
4. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism: international consensus statement-guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37.
5. Prandoni P, Lensing AW, Cogo A, et al. The long-term course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
6. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-8.
7. Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med 1998;3:57-60.
8. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-93.
9. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost effectiveness. Ann Surg 1980;191: 207-18.
10. Hull R, Hirsh J, Sackett DL, Stoddart G. Cost-effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. N Engl J Med 1981;304:1561-7.
11. Donaldson C, Currie G, Mitton C. Cost-effectiveness analysis in health care: contraindications. BMJ 2002;325:891-4.
12. Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery: meta-analysis of studies using venographic assessment. Arch Intern Med 1993;153:2221-8.
13. Imperiale TF, Speroff T. A meta-analysis of methods to prevent VTE following total hip replacement. JAMA 1994;271:1780-5. (Erratum in JAMA 1995;273:288.)
14. Imperiale TF, Speroff T. A meta-analysis of methods to prevent VTE following total hip replacement. JAMA 1994;271:1780-5. (Erratum in JAMA 1995;273:288.)
15. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
16. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994;81:1742-6.
17. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987;257:203-8.
18. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health-Syst Pharm 1997;54:1185-90.
19. Hawkins DW, Langley PC, Krueger KP. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. Clin Ther 1998;20:182-95.
20. Saunders ME, Grant RE. Cost-effectiveness of low-molecular-weight heparin versus warfarin following hip replacement surgery. J Natl Med Assoc 1998;90:677-80.
21. Sullivan SP, Davidson BL, Kahn SR, et al. Cost-effectiveness of fondaparinux compared with enoxaparin against venous thromboembolism in patients undergoing major orthopedic surgery. Presented at the 44th annual meeting and expedition of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002.
22. Wade WE, Spruill WJ, Leslie RB. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am J Orthop 2003;32:201-5.
23. Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74.
24. Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health-Syst Pharm 2002;59:1750-4.
25. Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med 1998;158:873-8.
26. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHLON 2000 Study Steering Committee. Post-operative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-6. (Erratum in Lancet 2002;360:1102.)
27. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHLON 2000 Study Steering Committee. Post-operative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-6. (Erratum in Lancet 2002;360:1102.)
28. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG, for the European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359: 1715-20.
29. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
30. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304.
31. Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003;21:477-96.